• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Italian Journal of Medicine >Antirheumatic in SARS-CoV-2: benefit or risk?
【24h】

Antirheumatic in SARS-CoV-2: benefit or risk?

机译：在SARS-COV-2中的Attrheumatic：福利或风险？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

About 300 million people worldwide are affectedby rheumatic diseases and over 5 and a half millionmen and women affected by rheumatological diseasesare present in Italy. These are chronic diseases andtherefore require treatments and diagnostic tests forlong periods of time. The needs of these patients mustbe met even in these difficult months marked by theCOVID-19 pandemic. The guarantee of continuity oftreatment is important and increasingly dangerous isthe lack of many drugs. This deficiency is due to thefact that many antimalarial and anti-inflammatorydrugs have entered the protocols for the treatment ofpeople with SARS-CoV-2. Without taking these medicines, which for years have also been used in rheumatology, there is a risk of reactivating serious diseasessuch as rheumatoid arthritis, ankylosing spondylitis orsystemic lupus erythematosus in people who havebeen under chronic treatment for years.
机译：世界各地约有3亿人口受到影响的风湿病，500万百万百万，患有风湿病疾病存在的妇女在意大利。这些是慢性疾病，因此需要治疗和诊断测试。甚至在这些困难的月份都会遇到这些患者的需求，这是由Thecovid-19大流行的困难数月。禁区连续性的保证是重要的，越来越危险的是缺乏许多药物。这种缺陷是由于许多抗疟和抗炎剂已进入与SARS-COV-2治疗的方案的方案。不服用这些药物，这些药物也已经用于风湿病学，存在重新激活严重的不安全作为类风湿性关节炎，强直性脊柱炎或系统狼疮红斑狼疮在慢性治疗中的人们患者多年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号